Fulcrum Therapeutics, Inc. (FULC)
| Market Cap | 496.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -76.12M |
| Shares Out | 66.63M |
| EPS (ttm) | -1.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 676,338 |
| Open | 7.81 |
| Previous Close | 7.72 |
| Day's Range | 7.42 - 7.98 |
| 52-Week Range | 3.45 - 15.74 |
| Beta | 3.27 |
| Analysts | Buy |
| Price Target | 16.38 (+120.01%) |
| Earnings Date | Apr 27, 2026 |
About FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for FULC stock is "Buy." The 12-month stock price target is $16.38, which is an increase of 120.01% from the latest price.
News
Fulcrum Therapeutics Earnings Call Transcript: Q1 2026
Positive phase I-B data for pociredir in sickle cell disease showed robust HbF increases, reduced VOCs, and good tolerability. Cash runway extends into 2029, supporting next-phase trials, with long-term data expected in 2027.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlu...
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve...
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to imp...
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis Three-year collaboration is aimed at enhancing a key aspect of sickle cell m...
Fulcrum Therapeutics Transcript: Leerink Global Healthcare Conference 2026
PIONEER study data showed strong HbF induction, VOC reduction, and a favorable safety profile, generating positive feedback and interest for future trials. The next step is a pivotal registrational study with interim analysis for accelerated approval, while business focus remains on sickle cell disease and U.S. commercialization.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives o...
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to imp...
Fulcrum Therapeutics Earnings Call Transcript: Q4 2025
The 20-mg cohort in the PIONEER trial showed robust HbF induction, improved anemia and hemolysis, and encouraging VOC reduction, with pociredir well-tolerated and poised for late-stage trials. Plans are underway for global expansion and regulatory engagement.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular H...
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve th...
Fulcrum Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Pociredir, an oral fetal hemoglobin inducer, showed robust HbF increases and improved clinical markers in sickle cell patients, with over half reaching transformative HbF levels and a strong safety profile. A registrational phase 3 study and open-label extension are planned for 2024.
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve th...
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improv...
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve ...
Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results
Fulcrum Therapeutics Inc. (NASDAQ: FULC) stock is surging on Monday, after the company released initial results from the ongoing 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle ...
Fulcrum Therapeutics Transcript: Status Update
The 20 mg dose of pociredir demonstrated robust and rapid increases in fetal hemoglobin, significant reductions in anemia and hemolysis, and encouraging trends in reducing VOCs, with a strong safety profile. Plans are in place for regulatory engagement, an open-label extension, and a registrational study.
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week...
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of...
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ―
Fulcrum Therapeutics Earnings Call Transcript: Q3 2025
Lead program pociredir showed strong Phase I-B results in sickle cell disease, with robust increases in fetal hemoglobin and favorable safety. Cash reserves of $200.6M are expected to fund operations into 2028, supporting ongoing clinical and preclinical programs.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) ...
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to impr...
Fulcrum Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A novel oral therapy for sickle cell disease demonstrated robust increases in fetal hemoglobin, significant reductions in pain crises, and a strong safety profile in early clinical data. Next steps include higher-dose cohort results by year-end and potential advancement to registrational studies.